Large pharmaceutical organizations require consistency, transparency and scalability. Syneos Health supports enterprise ...

A launch can meet every deadline and still fall short of its expected trajectory. Readiness reviews confirm that plans, materials, and training are in place. They do not necessarily tell us whether ...

Psychedelic therapies are advancing toward potential regulatory review and commercialization, creating new expectations for how clinical programs are designed, executed and evaluated. Unlike ...

Disruption in the patient services landscape is prompting biopharmaceutical manufacturers to reassess their patient support strategies. While maintaining continuity of care and minimizing operational ...

In a vaccine study, the right sites must be ready at the right time—and every potential endpoint event must be captured and documented. Delays in activation, gaps in surveillance or missing specimens ...

For emerging biopharmaceutical companies, risk-based quality management (RBQM) is more than a regulatory requirement. It is an opportunity to strengthen clinical trial oversight, protect timelines and ...

Discover how AI and digital workers are reshaping commercial operations. In this webinar, Syneos Health and causaLens experts use targeting and territory alignment to demonstrate how AI can speed ...

Early phase oncology trials are becoming more complex as sponsors face growing pressure to optimize dose selection, identify the right patients, generate stronger evidence and control execution risk — ...

MORRISVILLE, N.C., August 18, 2026 – Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem – a unified, ...

Oncology is entering a new phase of clinical development. The biggest story coming out of ASCO 2026 wasn’t a single breakthrough, but a series of shifts changing how therapies are discovered, ...

In this episode of The Syneos Health Podcast: Conversations on Commercialization, host Tyler Cowan, VP, Commercial is joined by Dr. Natalia Barkalina, Medical Director, and Gareth Powell, Clinical ...

If AI had to explain your brand first, would it say what you intended? AI is now part of how stakeholders encounter brands. Unlike people, it reads, pattern-matches and compresses public information ...